Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
- Gianni, Luca
- Dafni, Urania
- Gelber, Richard
- Azambuja, Evandro
- Muehlbauer, Susanne
- Goldhirsch, Aron
- Untch, Michael
- Smith, Ian
- Baselga, José
- Jackisch, Christian
- Cameron, David A
- Mano, Max S.
- Pedrini, José Luiz
- Veronesi, Andrea
- Mendiola, Cesar
- Pluzanska, Anna
- Semiglazov, Vladimir
- Vrdoljak, Eduard
- Eckart, Michael J
- Shen, Zhenzhou
- Skiadopoulos, George
- Procter, Marion
- Pritchard, Kathleen
- Piccart-Gebhart, Martine
- Bell, Richard H
- Herceptin Adjuvant (HERA) Trial Study Team
DOIAbstract
Treatment with adjuvant trastuzumab for 1 year improves disease-free survival and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess disease-free survival and overall survival after a median follow-up of 4 years for patients enrolled on the Herceptin Adjuvant (HERA) trial.Clinical Trial, Phase IIIJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tSCOPUS: ar.jinfo:eu-repo/semantics/publishe
Add to ORKG